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Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway inﬂam-
mation and/or airﬂow limitation due to pulmonary emphysema. Chronic bronchitis,
pulmonary emphysema, and bronchial asthmamay all be associated with airﬂow limitation;
therefore, exacerbation of asthma may be associated with the pathophysiology of COPD.
Furthermore, recent studies have suggested that the exacerbation of asthma, namely
virus-induced asthma, may be associated with a wide variety of respiratory viruses.
COPD and asthma have different underlying pathophysiological processes and thus
require individual therapies. Exacerbation of both COPD and asthma, which are basically
deﬁned and diagnosed by clinical symptoms, is associated with a rapid decline in lung
function and increasedmortality. Similar pathogens, including human rhinovirus, respiratory
syncytial virus, inﬂuenza virus, parainﬂuenza virus, and coronavirus, are also frequently
detected during exacerbation of asthma and/or COPD. Immune response to respiratory viral
infections, which may be related to the severity of exacerbation in each disease, varies in
patientswith bothCOPDand asthma. In this regard, it is crucial to recognize and understand
both the similarities and differences of clinical features in patientswith COPDand/or asthma
associated with respiratory viral infections, especially in the exacerbative stage. In relation
to deﬁnition, epidemiology, and pathophysiology, this review aims to summarize current
knowledge concerning exacerbation of both COPD and asthma by focusing on the clinical
signiﬁcance of associated respiratory virus infections.
Keywords: asthma, COPD, respiratory virus, exacerbation, overlap syndrome, human rhinovirus, respiratory
syncytial virus
INTRODUCTION
Asthma and chronic obstructive pulmonary disease (COPD) are
very common inﬂammatory diseases of the airways. The World
Health Organization (WHO) estimates that asthma accounts for 1
in every 250 deaths worldwide (O’Sullivan, 2005). The prevalence
of asthma in developed countries is approximately 10% in adults
and even higher in children, while in developing countries, the
prevalence is lower but increasing rapidly (Barnes, 2008). In the
case of COPD,WHO consensus reports forecast that this disorder
will be ranked the third cause of mortality in the world by 2020
(Global initiative for chronic obstructive lung disease [GOLD],
20131). Acute deteriorationof symptoms and lung function,which
often results in respiratory failure, is a so-called“exacerbation,”and
it is an important and severe social and medical burden in both
diseases.
Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; AdVs, aden-
oviruses; BAL, bronchoalveolar lavage; COPD, chronic obstructive lung disease;
CRP, C-reactive protein; FEV1.0, forced expiratory volume in 1 second; GOLD,
Global initiative for chronic obstructive lung disease; HMPV, human metapneu-
movirus; HRV, human rhinovirus; ICS, inhaled corticosteroid; IFN, interferon;
IL, interleukin; LABA, long-acting β-agonist combination; LAMA, long-acting
muscarinic antagonist; LRT, lower respiratory tract; NPS, nasopharyngeal swabs;
NPW, nasopharyngeal washings; OPS, oropharyngeal swabs; PEFR, peak expiratory
ﬂow rate; PIV, parainﬂuenza virus; RSV, respiratory syncytial virus; RTI, respi-
ratory tract infection; RT-PCR, reverse-transcriptase polymerase chain reaction;
SABA, short-acting β-agonist inhaler; TLR, toll-like receptor; TLSP, thymic stromal
lymphopoietin; URT, upper respiratory tract.
1http://www.goldcopd.org/uploads/users/ﬁles/GOLD_Report_2013_Feb20.pdf
Respiratory viral infections are common and usually self-
limiting illnesses in healthy adults and a major cause of
exacerbations in patients with asthma (Figure 1) and/or COPD
(Figure 2).
This review aims to summarize the clinical aspects of exacerba-
tions in asthma and COPD from the perspective of the deﬁnition
of exacerbations, epidemiology, and pathophysiology, with a spe-
cial focus on the clinical signiﬁcance of the presence of respiratory
viruses.
PATHOPHYSIOLOGY OF ASTHMA AND COPD
Asthma and COPD are prevalent chronic pulmonary diseases
characterized by chronic airway inﬂammation and airﬂow limita-
tion. The differences between the two diseases aremainly the cellu-
lar and molecular features of airway inﬂammation and the degree
of reversibility of airway ﬂow limitation. Generally, reversibility
of airﬂow limitation is incomplete in COPD, while that in asthma
can be complete. Airway inﬂammation in asthma is characterized
by allergic phenotypes, such as dense inﬁltration of eosinophils
and T helper type 2 lymphocytes, associated with atopic status,
while that of COPD is mainly accumulation of neutrophils, CD8-
positive cytotoxic T cells, and activated macrophages, which are
caused by inhalation of harmful substances, such as smoking.With
respect to the site of inﬂammation, asthma involves predominantly
larger airways, while in COPD, inﬂammation affects predomi-
nantly small airways and the lung parenchyma, characterized as
irreversible airway narrowing because of ﬁbrosis around the small
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FIGURE 1 | Human respiratory pathogens associated with asthma exacerbations. Pathogens are divided into three categories as bacteria, RNA viruses, or
DNA viruses. Red and yellow columns are the most relevant pathogens in order.
FIGURE 2 | Human respiratory pathogens associated with exacerbations of COPD. Red and yellow columns are the most relevant pathogens in order.
airways or destruction of alveolar walls with protease-mediated
degradation (Barnes, 2008). Of note, neutrophilic inﬁltration
could be recognized in bronchial biopsied specimens as well as
eosinophils in severe refractory asthma (Wenzel et al., 1999).
DIFFERENCES AND SIMILARITIES BETWEEN ASTHMA
AND COPD
As described above, asthma is typically characterized by chronic
allergic inﬂammatory airway inﬂammation associated with airway
hyperresponsiveness that leads to recurrent episodes of bronchial
obstruction. In contrast, COPD is characterized by persistent
airﬂow limitation that is usually progressive and ultimately results
in respiratory failure. Therefore, it is not difﬁcult to differenti-
ate clinically between the two disorders. However, determining
whether a patient has asthma or an exacerbation of COPD is often
difﬁcult, because of their clinical similarity. The Table 1 summa-
rizes the differences between these two diseases, and Tokuda and
Miyagi (2007) provided an excellent review of rapid physical diag-
nosis for COPD patients that focused on inspection, palpation,
percussion, auscultation, special maneuvers, and vital signs.
On physical examination, the sound of an expiratory wheeze is
identical in asthma, COPD, congestive heart failure, and pneumo-
nia, and it cannot be used to distinguish among these conditions
(Kaplan et al., 2009). Thus, physical examination is relatively
insensitive for the diagnosis of asthma, but COPD has its char-
acteristic physical ﬁndings (Tokuda and Miyagi, 2007) that could
be useful in rapid differentiation from those of asthma.
Recent understanding of the innate immune system suggests
that it may function independently of the adaptive immune sys-
tem in some cases or synergistically in others, and the relative
contributions of the two systems may explain the disease hetero-
geneity among asthmatic patients, which might occur in patients
with COPD (Holtzman, 2012). It has long been argued that
asthma, chronic bronchitis, and emphysema could be considered
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Table 1 | Differences between asthma and COPD.
Asthma COPD
Age at onset At any age (usually <40 years) Usually >40 years
Smoking history Possible Usually >10 pack-years
Cough at exacerbation Usually between 2 and 6 am Gradual increase
Sputum production Infrequent Common
Allergy(eczema or allergic rhinitis) Common Infrequent
Airway inflammation
Main portion Large airways Small airways
Pathophysiology Basement-membrane thickening
Increased airway smooth muscle
Fibrosis of small airways
Destruction of alveolar walls
Bronchial biopsies Th2-dominant T cells
Eosinophils, activated mast cells
Th1-dominant T cells and type1 CTL
Neutrophils and Mϕ
Reversibility (peak ﬂow results) Normalize with time May improve, but do not normalize
Family history Common Uncommon
CTL, cytotoxic T cell; Mϕ, macrophage.
as different expressions of one disease entity. This view is called
the “Dutch hypothesis” (Kraft, 2006), and it is still under debate,
with no consensus about it. There are many similarities in asthma
and COPD (Bleecker, 2004), and previous studies suggested that
asthma may be a risk factor for the development of COPD (Silva
et al., 2004), while the coexistence of asthma and COPD, so-called
“overlap syndrome,” has recently been attracting attention. Over-
lap syndrome accounts for about 15–25% of obstructive airway
disease (Louie et al., 2013) and shows more frequent or severe
exacerbations and higher mortality than COPD alone (Hospers
et al., 2000; Hardin et al., 2011). Furthermore, previous reports
noted that exacerbations of asthma or COPD are associated with
accelerated loss of lung function and quality of life and increased
healthcare costs and mortality.
Thus, it is crucial to recognize and understand the clinical fea-
tures of asthma and COPD patients, not only in the stable phase,
but also in exacerbated phases associated with respiratory viral
infections. Johnston and Sears (2006) reported that exacerbations
of asthma and COPD appear to have a seasonal predilection in a
similar fashion.
VIRUS-INDUCED EXACERBATIONS IN ASTHMA AND COPD
VIRUS-INDUCED EXACERBATIONS IN ASTHMA
In bronchial asthma, acute exacerbation involves several issues
(Figure 3), such as the deﬁnition of acute exacerbation of asthma,
recognition of the clinical symptoms of respiratory tract infection
(RTI), assessment of the risk factors for acute exacerbation, con-
sidering the possibility of other diseases (differential diagnosis),
diagnostic methods, appropriate sample collection, and treatment
or prevention. An older study showed that asthmatic patients had
a 6.2 times greater chance of having viral RTIs than a control
group (Abramson et al., 1994), while Corne et al. (2002) found
that the detection rates of human rhinovirus (HRV) in asthmatic
(10.1%) and healthy participants (8.5%) were similar. The term
virus-induced exacerbation of asthma is not uncommon, but only
a small number of such studies were prospective (Nicholson et al.,
1993; Johnston et al., 1995). Furthermore, RTIs do not always lead
to an exacerbation, and there is little evidence that treating or
preventing the infection may cure or prevent an exacerbation. In
this regard, we mainly discuss the details of “viral infection and
exacerbation of asthma,” focusing on the accumulation of useful
expertise for understanding this unfavorable condition in adult
asthmatic patients.
Deﬁnitions of acute exacerbation of asthma
The diagnosis of asthma is usually deﬁned based on history
and variability of the peak expiratory ﬂow rate (PEFR) and/or
of forced expiratory volume in 1 s (FEV1.0) of at least 20%,
either with therapy or spontaneously. There is no clear con-
sensus deﬁnition for asthma exacerbation; clinical trials usually
deﬁne a severe exacerbation as the need for treatment with
systemic corticosteroids, hospital admission, or emergency treat-
ment for worsening asthma, or a decrease in morning peak ﬂow
>25% baseline on two consecutive days (O’Byrne et al., 2001).
According to the latest NIH National Asthma Education and
Prevention Guidelines, asthma exacerbations are acute or sub-
acute episodes of progressively worsening shortness of breath,
cough, wheezing, and chest tightness, or some combination of
these symptoms, characterized by decreases in expiratory air-
ﬂow and objective measures of lung function (spirometry and
peak ﬂow) (National Asthma Education and Prevention Pro-
gram, 2007), identical to the deﬁnition of the Global Initiative
for Asthma guidelines (2012)2 (Figure 3). However, a joint task
force of the American Thoracic Society and European Respira-
tory Society has recently deﬁned asthma exacerbations as events
characterized by a change from the patient’s previous status (Red-
del et al., 2009). Severe exacerbations were deﬁned as events that
require urgent action to prevent hospitalization or death, whereas
moderate exacerbations were deﬁned as the status of an asthmatic
patient who required a prompt change in treatment due to being
outside the patient’s usual range of day-to-day asthma variation.
Mild exacerbations are not deﬁned because such events can be
2http://www.ginasthma.org/local/uploads/ﬁles/GINA_Report_March13.pdf
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FIGURE 3 | Multidisciplinary assessment for asthma exacerbation. PCR,
polymerase-chain reaction; RT-PCR, real-time PCR; BALF, bronchoalveolar
lavage ﬂuid; GERD, gastroesophageal reﬂux disease; ASA, acetylsalicylic acid;
NSAIDS, non-steroidal anti-inﬂammatory drugs; SABA, short-acting β-agonist
inhalers; GINA, Global Initiative for Asthma; ABPA, allergic bronchopulmonary
aspergillosis; EPR, expert panel report.
indistinguishable from loss of asthma control (Reddel et al., 2009;
Figure 3).
Epidemiology
Asthma exacerbations are more common in female than in male
patients, and the higher prevalence of asthma in adult women
contrasts with the higher prevalence of asthma in male children
(Bjornson and Mitchell, 2000). Between 14 and 45% of acute
asthma exacerbations in children is thought to be related to viral
RTIs. Although the incidence in adults is less clear, previous reports
showed that RTIs associated with asthma exacerbation in adults
ranged from 10–21% (Teichtahl et al., 1997) to 45–80% (Johnston
et al., 1995; Atmar et al., 1998), of which 60% have HRV (Johnston
et al., 1995; Atmar et al., 1998; Tan, 2005; Figure 1). Despite their
widely differing designs, these studies suggest that viral infections
are involved in about 50% of asthma exacerbations among adults
and in probably substantially more childhood asthma exacerba-
tions. Another report also showed that the virus most commonly
implicated in asthma exacerbations appears to be HRV (Murray
et al., 2004). In addition to HRV, other respiratory tract viruses,
such as respiratory syncytial virus (RSV), inﬂuenza viruses, coro-
naviruses, human metapneumoviruses (HMPVs), parainﬂuenza
viruses (PIVs), adenoviruses (AdVs), and bocaviruses, have all
been detected in subjects with asthma exacerbations (Jackson and
Johnston, 2010). In adults requiring hospital admission for an
acute severe asthma exacerbation in a 1-year period, virus was
identiﬁed in 29% of the subjects, with HRV and inﬂuenza A
the most commonly identiﬁed infectious agents (Teichtahl et al.,
1997).
Diagnosis of viral infection: diagnostic methods and sample
collection
Molecular methods of viral detection have superior sensitivity
and speciﬁcity compared to cell culture-basedmethods (McErlean
et al., 2010). In the setting of acute exacerbation, the reverse-
transcriptase polymerase chain reaction (RT-PCR) method can
detect viruses in approximately 80% of wheezing episodes in
school-aged children and in approximately one-half to three-
quarters of acute wheezing episodes in adults (Jackson and
Johnston, 2010).With respect to sample collections for viral detec-
tion, Xiang et al. (2002) reported that nasopharyngeal secretions
and induced sputum during acute exacerbations of asthma in
adult patients were equal, while Falsey et al. (2012) found that
the diagnostic yields using RT-PCR for detection of any virus
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in adults hospitalized with respiratory illness were superior in
sputum samples (36%) than in nose and throat swabs (23%).
However, the study had some limitations in that no test for HRV
or AdVs was used. Another report showed that the sensitivity rates
for oropharyngeal swabs (OPS), nasopharyngeal swabs (NPS),
and nasopharyngeal washings (NPW) obtained from hospitalized
patients with acute febrile lower respiratory tract (LRT) infections
were 54.2, 73.3, and 84.9%, respectively (for OPS vs. NPS and
NPW, p < 0.00001; for NPS vs. NPW, p < 0.003; Lieberman et al.,
2009). Taken together, these studies appear to suggest that induced
sputum andNPS/NPW are better methods for identifying respira-
tory viruses. Regarding HRV, bronchoalveolar lavage (BAL) cells
were positive for HRV RNA during infection in 80% of samples,
whereas nasal lavage ﬂuid was positive in the same patients in
100%, and BAL ﬂuid was positive in only 37%. This suggests that
HRV is able to infect the lower airways, and that HRV RNA is
largely cell-associated (Murray et al., 2004).
Causes of acute asthma exacerbations
Eczema and a family history of asthma are the dominant non-
infectious risk factors for pediatric asthma, while the triggers of
adult-onset disease are less well deﬁned. The causes for asthma
exacerbation have been described and categorized. Of note, clin-
icians should recognize the seasonal trends for exacerbations of
wheezing or asthma in adults, which occur 1–2 weeks later than
in children, suggesting household transmission of the same strain
(Johnston et al., 1996). HRV can be documented throughout the
year, with a predilection for late spring and fall (Nagel et al., 2008),
whereas RSV can be detected in late autumn to winter (Figure 1).
Viruses. The most important viruses relevant to asthma develop-
ment are RSV andHRV. Jackson et al. (2008) demonstrated that, in
a large, high-risk cohort, children had an increased risk of asthma
at 6 years of age if they wheezed in the ﬁrst 3 years of life with
RSV [odds ratio (OR) 2.6], HRV (OR 9.8), or both HRV and RSV
(OR 10).
Respiratory syncytial virus. By 1 year of age, 50–65% of children
will have been infected with this virus, and by 2 years of age, nearly
100%has been infected (Openshaw, 1995). The exactmechanisms
by which respiratory viral infection causes asthma exacerbation
remains to be determined, but the respiratory viruses implicated in
exacerbations have themselves been largely identiﬁed (Figure 1).
The role of severe RSV infection as a risk factor for asthma in
adulthood is less certain, but it is still under study. RSV is an
important pathogen of young children and accounts for ∼70% of
severe infantile viral bronchiolitis and/or pneumonia cases, most
of whom have wheezing, and it is the most common cause of
hospital admission in the winter season during the ﬁrst year of
life (Blanken et al., 2013). Furthermore, this study showed the
strongest evidence that human RSV-mediated bronchiolitis has
long-term effects using palivizumab (a humanized monoclonal
antibody against RSV F protein that prevents infection by RSV in
infancy). In children under 5 years, RSV and PIV are the most
common pathogens, whereas in older children, rhinovirus and
inﬂuenza A virus are more prevalent (Beasley et al., 1988). Even
in elderly persons, RSV causes pneumonia (Falsey et al., 2006),
exacerbations of COPD, and acute deterioration in those with
cardiac disease, and it contributes substantially to excess deaths in
the winter season (Olszewska and Openshaw, 2009).
Human rhinovirus. Recent studies have identiﬁed infection with
HRV as a predominant respiratory pathogen associated with
asthma later in life (Kusel et al., 2007). HRV is the most impor-
tant virus type associated with exacerbations of asthma leading
to hospital admission in both adults and children (Johnston
et al., 1996). Tan et al. (2003) reported that picornaviruses (rhi-
novirus/enterovirus) and AdV were most commonly identiﬁed
in near-fatal asthma, whereas inﬂuenza virus predominated in
COPD. Corne et al. (2002) found that the detection rates of HRV
in asthmatic (10.1%) and healthy participants (8.5%)were similar,
but the LRT symptoms were signiﬁcantly more severe and longer-
lasting in the asthmatic group than in the healthy group. Thus,
HRV is the most common and important cause of exacerbation in
both children and adults (Johnston et al., 1996; Rakes et al., 1999;
Copenhaver et al., 2004; Message et al., 2008; Dougherty and Fahy,
2009; Olenec et al., 2010; Jackson et al., 2012). HRV can now be
classiﬁed into three species (HRV-A, B, and C) based on their
genetic properties (http://www.ictvonline.org/), while over 100
serotypes have been identiﬁed. Molecular epidemiological stud-
ies suggest that HRV-A and -C are the major prevalent species,
with wide genetic divergence (Fujitsuka et al., 2011).
Adenoviruses.Adenoviruses are well known as a primary cause of
acute respiratory infection, particularly in young children. AdVs
are associated with up to 7% of virus-related asthma exacerba-
tions (McErlean et al., 2010), and they cause a wide variety of
clinical syndromes, such as diarrhea, keratoconjunctivitis, and
hemorrhagic cystitis (Brodzinski and Ruddy, 2009). It has been
demonstrated that 94% of children with refractory asthma has
detectable AdV antigens, compared with 0% of controls (Macek
et al., 1994; Figure 1).
Parainﬂuenza virus.As previously noted, PIV is one of the most
common pathogens for asthma exacerbation in children under
5 years. In adults with asthma, PIV infections have also been com-
monly demonstrated in several longitudinal studies of RTIs, but
they have been identiﬁed less commonly in studies of patients seen
in the hospital or emergency department (Atmar et al., 1998).
Other viruses. Most asthma studies describe relatively low levels of
inﬂuenza viruses in asthmatic patientswith exacerbations, approx-
imately 1–9% of all virus-related asthma exacerbations. Several
studies indicated that human bocaviruses (Gendrel et al., 2007;
Vallet et al., 2009) and HMPV (Williams et al., 2005; Ong et al.,
2007) are associated with exacerbations of asthma, especially in
children.
Bacteria. Mycoplasma pneumoniae and Chlamydophila pneumo-
niae are found more frequently in the airways of patients with
asthma than in healthy patients (Nisar et al., 2007), but their role
in exacerbations is less clear (Xepapadaki et al., 2008). In previous
studies, some have reported mycoplasmal infection in up to 25%
of children with wheezing (Henderson et al., 1979) or identiﬁed it
in 20% of exacerbations in asthmatic children requiring hospital-
ization and in 50% of children experiencing their ﬁrst asthmatic
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attack (Biscardi et al., 2004). However, others have not been able
to conﬁrm these observations (Cunningham et al., 1998).
Other speciﬁc pathogens, including Haemophilus inﬂuenzae,
Streptococcus pneumoniae, Pseudomonas aeruginosa, Moraxella
catarrhalis, HRV, and RSV, have been shown to increase mucus
secretion, which is recognized in asthma or COPD by character-
istic goblet cell hyperplasia or enhanced mucus secretion (Fahy,
2002; Bisgaard et al., 2007; Kraft et al., 2008).
Fungus.Allergic bronchopulmonary aspergillosis (ABPA) is a
unique form of asthma caused by colonization of the LRT (Vla-
hakis and Aksamit, 2001). ABPA is caused by an exaggerated T
helper type 2 response to the ubiquitous mold Aspergillus spp.,
by which colonization leads to allergic and/or asthma symptoms
(Edwards et al., 2012).
Other factors. The diverse etiologies for asthma exacerbation
are well known, including viruses, allergens (dust mite, pollen,
animal dander), smoking, gastroesophageal reﬂux disease, obe-
sity, rhinosinusitis, stress, occupational exposures, hormones
(menstrual asthma), drugs (acetylsalicylic acid, non-steroidal
anti-inﬂammatory drugs, beta-blockers), exercise, and air pollu-
tants. Physicians should be aware of these risk factors for asthma
exacerbation (Dougherty and Fahy, 2009).
Mechanisms of viral-induced asthma exacerbations
Respiratory virus infection affects the pathogenesis of asthma.
Bronchial epithelial cells are at the site of respiratory virus infection
and replication. Respiratory virus infection induces production of
various cytokines or chemokines and causes injury to epithelial
cells or disruption of tight junctions. This inﬂammatory pro-
cess may be ampliﬁed by intrinsic factors (susceptibility gene,
family history of atopy, lung development) or environmental fac-
tors (respiratory virus infection, allergen exposure, smoking, and
air pollutants, etc.; Hashimoto et al., 2008; Dougherty and Fahy,
2009). Some studies showing a deﬁciency in interferon (IFN)-β
and IFN-λ production in response to HRV inoculation in airway
epithelial cells cultured from asthmatic versus normal subjects
(Holtzman, 2012) suggested that asthmatic patients have deﬁcient
IFN-β, IFN-λ, and perhaps some of the IFN-αs, but the precise
mechanism or mechanisms behind deﬁcient IFN production in
these patients remain unknown.
Virus-associated clinical symptoms and exacerbations
of asthma
In general, upper respiratory tract (URT) symptoms include rhi-
norrhea, sneezing, blocked nose, sore throat, hoarse voice, head or
face ache, chill, and fever, while LRT symptoms include symptoms
such as wheeze, cough, shortness of breath, and chest tightness
(Corne et al., 2002). Tan et al. (2003) reported that virus-positive
patients had a signiﬁcantly increased frequency of URT symptoms
of rhinorrhea, sore throat, fever, chills, and malaise. Nicholson
et al. (1993) reported that, in adults with asthma, about a quarter
of laboratory-conﬁrmed viral and chlamydial acute upper res-
piratory infections was associated with mean decreases in peak
expiratory ﬂow of > 50 L/min, and half was associated with
mean decreases of >25 L/min. The report also noted that res-
piratory pathogens were implicated in almost half of the most
severe asthma exacerbations with a > 50 L/min mean decrease
in peak expiratory ﬂow. Viral infections have been shown to
enhance both the reactivity of the lower airway and the magni-
tude of bronchoconstriction in response to inhaled contractile
substances in asthma. The latter effect can persist for several weeks
after infection, presenting as LRT symptoms (Cheung et al., 1995)
accompanied by a decrease in peak expiratory ﬂow. Thus, physi-
cians should be aware of decreased peak expiratory ﬂow, URT, or
LRT symptoms associated with viral infections.
Treatment
The term “virus-induced exacerbation” is not uncommon, but
only a small number of prospective studies have been conducted
so far (Nicholson et al., 1993; Johnston et al., 1995). Importantly,
respiratory infections do not always result in an exacerbation, and
there is little evidence that treating or preventing the infectionmay
cure or prevent an exacerbation (Xepapadaki and Papadopou-
los, 2010). However, another study found that URT infections
were strongly associated with exacerbations of asthma leading
to hospital admission, in both adults and children (Johnston
et al., 1996), and they may have contributed to asthma mor-
tality, especially in the setting of hospital admission. Speciﬁc
anti-viral therapies have not been established except for inﬂuenza
viral infection, which have been recommended for persons with
asthma or COPD. Furthermore, regarding preventive therapy for
RSV, palivizumab as described above is now commercially avail-
able, and it might be appropriate for infants and young children
with congenital heart disease, bronchopulmonary dysplasia, and
prematurity before 35 weeks of gestation (Dawson-Caswell and
Muncie, 2011). Blanken et al. (2013) stated that palivizumab treat-
ment in healthy preterm infants born at a gestational age of 33–
35weeks reduced thenumberof wheezingdays during theﬁrst year
of life.
In this regard, several therapeutic strategies would need to
be taken early in the course of infection to maximize the
effects of treatments such as systemic corticosteroids, antibiotics
if necessary, and short-acting β-agonist inhalers (SABAs), fol-
lowed by inhaled corticosteroid (ICS) and long-acting β-agonist
combination (LABA) therapy. Kerstjens et al. (2012) reported
that additive long-acting muscarinic antagonist (LAMA) therapy
with tiotropium (known as a cornerstone of COPD treatment)
signiﬁcantly increased the time to the ﬁrst exacerbation and
improved FEV1.0 in poorly controlled asthmatic patients with
standard therapy (ICS and LABA). Similarly, tiotropium improved
lung function and reduced the chance of rescue inhaler (SABA) in
patients with overlap syndrome (Magnussen et al., 2008).
VIRUS-INDUCED EXACERBATIONS IN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
DEFINITION OF EXACERBATION IN COPD
Exacerbation of COPD is an event characterized by an acute
increase in respiratory symptoms beyond normal day-to-day vari-
ation (Vestbo et al., 2013). Clinicians and researchers should always
keep in mind that exacerbations of COPD are neither deﬁned
consistently nor matched in individual studies. Deﬁnitions of
exacerbations are roughly divided into two groups, event-based
exacerbations and symptom-based exacerbations, depending on
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the patients’ symptoms or clinical events, respectively. Symptoms
were deﬁned and include dyspnea, cough, and sputum volume or
purulence. Clinical events were deﬁned as a status requiring addi-
tional treatments such as systemic antimicrobials or steroids with
or without admission. Diseases such as pneumonia, congestive
heart failure, and pulmonary embolism that mimic and/or aggra-
vate exacerbations were generally excluded from exacerbations of
COPD.
CLINICAL IMPORTANCE OF EXACERBATION
The clinical course of COPD, as well as that of asthma, is
punctuated by exacerbations, which are characterized by sudden
symptom worsening beyond the expected daily variation. Exac-
erbations are important events in the clinical course of COPD,
because they are associated with signiﬁcant mortality. The in-
hospital mortality rate of patients admitted to the hospital with
exacerbations of COPD was 8%, increasing to 23% after 1 year
of follow-up (Groenewegen et al., 2003). Exacerbations are cor-
related with accelerated loss of lung function and quality of life
and increased healthcare costs (Seemungal et al., 1998; Donaldson
et al., 2002; Miravitlles et al., 2002).
FREQUENCY OF EXACERBATIONS
Previous studies showed that the annual rate of event-based exac-
erbations of COPD was 0.85–1.30 per patient per year (Calverley
et al., 2007; Tashkin et al., 2008; Wedzicha et al., 2008; Seemungal
et al., 2009; Hurst et al., 2010). The INSPIRE study showed that the
rate of symptom-based exacerbations was about two times as high
as that of event-based exacerbations (Seemungal et al., 2009). In
the ECLIPSE study, the exacerbation rates were 0.85 per person for
patients with moderate disease (GOLD stage 2) and 2.00 for those
with very severe disease (GOLD stage 4; Hurst et al., 2010). Thus,
the rate of exacerbation seems to depend on the disease sever-
ity (GOLD stage). However, it is particularly worth noting that
the ECLIPSE study showed a subgroup of COPD patients that
appeared to be susceptible to exacerbations, irrespective of GOLD
stage. Other factors for exacerbations were several environmental
factors, such as seasons or inhalation of harmful substances, and
epidemic peaks in exacerbations of COPD were noted in both late
fall and winter in the same fashion as in adult asthma (Johnston
and Sears, 2006).
CAUSES OF EXACERBATIONS
It has been reported that exacerbations are predominantly caused
by bacterial and viral respiratory infections (Figure 2), and air
pollution has a minor contribution. Previous studies showed that
bacteria (H. inﬂuenzae, S. pneumoniae, Moraxella catarrhalis, and
P. aeruginosa) and respiratory viruses (HRV, RSV, inﬂuenza virus,
HMPV, coronavirus, and AdVs) were recognized during exacer-
bations. Bacteria, such as H. inﬂuenzae, S. pneumoniae, Moraxella
catarrhalis, and P. aeruginosa were also detected in stable patients
(Sapey and Stockley, 2006; Sethi andMurphy, 2008).When strains
of bacteria are changed among the same species or there is emer-
gence of other bacteria, this might cause inﬂammation in the lung
in COPD patients and result in exacerbation (Sethi et al., 2002).
The role of atypical respiratory pathogens, such as Mycoplasma
pneumoniae and C. pneumoniae, in exacerbations of COPD is
poorly recognized (Sapey and Stockley, 2006; Sethi and Murphy,
2008; Perotin et al., 2013). On the other hand, Blasi et al. (2002)
showed that C. pneumoniae may be associated with exacerbation
of COPD. Viruses such as HRV, RSV, and inﬂuenza virus have a
higher prevalence in patients with exacerbations of COPD than in
stable patients (Rohde et al., 2003; Wilkinson et al., 2006a).
ROLES OF RESPIRATORY VIRAL INFECTION IN COPD
EXACERBATIONS
A few decades ago, it was considered that the role of respira-
tory viral infections was not a major cause in exacerbations of
COPD because of the low sensitivity for viral detection, which
depended on conventional technical methods such as viral culture
or serological tests. However, recent studies have used new diag-
nostic technologies such as PCR or RT-PCR methods, which have
a higher sensitivity for viral detection than conventional meth-
ods. Viral detections accounted for 22–57% of exacerbations of
COPD in recent studies(Figure 4) using PCR or RT-PCR with
observational periods of at least 1 year. The major viruses associ-
atedwith exacerbationswereHRV (3.1–26.6%), RSV (0.7–40.5%),
and inﬂuenza virus (2.0–22.4%; Seemungal et al., 2001; Rohde
et al., 2003; Tan et al., 2003; Beckham et al., 2005; Papi et al., 2006;
Hutchinson et al., 2007; Ko et al., 2007; McManus et al., 2008;
Kherad et al., 2010; Dimopoulos et al., 2012; Perotin et al., 2013).
Major respiratory viruses detected during exacerbations of
COPD were HRV, RSV, and inﬂuenza virus, similar to those of
FIGURE 4 |Viral detection in exacerbations of COPD using PCR or
RT-PCR methods in recent studies. Picornaviruses include human
rhinovirus and human enterovirus. Multiple viruses were detected in
individual patients per one episode.
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asthma (Tan et al., 2003). Other viruses, such as PIV, human
metapneumovirus, AdV, and coronavirus, were also noted in
patients with COPD exacerbations. The proportion of viral-
related exacerbations seemed to be similar among the vari-
ous GOLD stages, while that of bacteria-related exacerbations
increased with higher stage or a decrease in lung function
(Dimopoulos et al., 2012).
HRV
Human rhinovirus was the most detected virus during exacer-
bations of COPD, but not only HRV infection alone but also
co-infection with HRV and bacteria may cause exacerbations
(Wilkinson et al., 2006b). Mallia et al. (2011) reported that exper-
imental HRV infection showed more severe and prolonged lower
respiratory symptoms, airway obstruction, and neutrophilic air-
way inﬂammation inCOPDpatients than in control subjects. They
stated that rhinovirus infection led to elevation of neutrophil elas-
tase, which is associated with reduction of antimicrobial peptides,
such as secretory leukoprotease inhibitor and elaﬁn. This reduc-
tion of antimicrobial peptides predisposes to secondary bacterial
infection (Mallia et al., 2011, 2012).
Previous reports showed that COPD exacerbations may be
associated with an impaired host response to HRV. For exam-
ple, reduced IFN production was observed in COPD patients
compared to control subjects, which may be associated with the
mechanism of viral and subsequent bacterial infection related
to severe exacerbations. Impaired humoral immunity was also
related to exacerbation of COPD. Patients hospitalizedwithCOPD
exacerbations had lower serum levels of rhinovirus-speciﬁc anti-
bodies than those not hospitalized with COPD exacerbations
(Yerkovich et al., 2012). Thymic stromal lymphopoietin (TSLP)
is a key pro-allergic cytokine that has recently been linked to
asthma(Redhu and Gounni, 2012). In addition, genome-wide
association studies showed that polymorphisms near or within the
TSLP gene were associated with various allergic diseases, includ-
ing bronchial asthma (Hirota et al., 2011; Ober and Yao, 2011).
TSLP may contribute to exacerbations of the pathogenic effects of
HRV infection via a Toll-like receptor (TLR)3-dependent pathway
(Calven et al., 2012).
RSV
Respiratory syncytial virus has been detected in both stable and
exacerbated cases of COPD. RSV detection in stable COPD
patients might be associated with insidious airway inﬂammation
and accelerated decline in FEV1.0 (Wilkinson et al., 2006a). How-
ever, this was not conﬁrmed by another study (Falsey et al., 2006).
RSV increases the expression of TLR3 on the surface of airway
epithelial cells, which is associated with increased sensitization
to double-stranded RNA and its related infections (Groskreutz
et al., 2006).
Inﬂuenza virus
Inﬂuenza virus has been associated with mortality and morbid-
ity in chronic lung diseases (Harper et al., 2009). A meta-analysis
showed that inﬂuenza vaccination prevented exacerbations in
COPD patients (Poole et al., 2000) and reduced the mortality and
morbidity in elderly persons (Nichol et al., 2007). Anti-viral treat-
ment such as neuraminidase inhibitors may reduce the severity of
disease (Kaiser et al., 2003). Thus, treatment to prevent inﬂuenza
has been recommended for COPD patients (Harper et al., 2009).
ARE PATIENTS WITH COPD SUSCEPTIBLE TO RESPIRATORY VIRAL
INFECTIONS?
Greenberg et al. (2000) investigated viral infections with or with-
out COPD in a longitudinal cohort study. They demonstrated that
annual symptomatic documented respiratory viral infection rates
were similar for COPD and age-matched controls (0.45/year and
0.54/year, respectively). However, the COPD patients had more
ofﬁce visits and hospitalization than controls.
Of note,Mallia et al. (2011, 2012) conﬁrmed these ﬁndings in a
human experimental study; they found no signiﬁcant differences
in the frequencies of successful HRV infection between COPD and
control groups when these groups were experimentally inoculated
with HRV. Respiratory symptoms and a decline in lung function
were more severe in the COPD group than in the control group.
DIFFERENCES IN VIRAL AND NON-VIRAL EXACERBATIONS
Several studies have suggested that respiratory virus-associated
exacerbations are more critical events than those due to other
causes, in that viral-detected exacerbations showed a larger decline
in lung function and longer recovery time than non-viral exacer-
bations (Seemungal et al., 2001; Bafadhel et al., 2011). As described
in the chapter on HRV, respiratory viral infections themselves
exacerbated COPD patients and tended to provoke secondary
bacterial infections. Viral and sequential bacterial infections may
be associated with severe respiratory symptoms (Wilkinson et al.,
2006b; Harper et al., 2009; Mallia et al., 2012).
MECHANISMS OF VIRUS-INDUCED COPD EXACERBATIONS
As shown in the Table 1, the pathological features of COPD
are ﬁbrosis around small airways involving several different cells
(neutrophils, macrophage, CD8 lymphocytes) and destruction of
lung parenchyma. Neutrophils have been found to be associated
with both stable and exacerbated COPD (Hogg et al., 2004; Papi
et al., 2006).
Changes in neutrophil counts during exacerbations in both
sputum and peripheral blood have been found to be related to the
FEV1.0 value. Levels of tumornecrosis factor-alpha and interleukin
(IL)-8 in sputum were associated with neutrophilic inﬂammation
(Keatings et al., 1996). Especially in patients who suffered from
frequent exacerbations, they had persistently higher systemic IL-6
andC-reactive protein (CRP) levels, whichmay explain the greater
decline in lung function (Perera et al., 2007).
Inﬂammatory cytokines in sputum during exacerbations have
been found to be elevated regardless of whether the infection
is viral or bacterial (Aaron et al., 2001), and their levels were
higher with exacerbations than when stable. Eosinophils are con-
sidered characteristic cells in asthma, but they are also detected
with exacerbations of COPD (Saetta et al., 1994). Indeed, Papi
et al. (2006) demonstrated that virus-associated exacerbations in
COPD patients were related to increased eosinophil counts and
the level of eosinophil cationic protein. Furthermore, Bafad-
hel et al. (2011) showed that serum C-X-C motif chemokine 10
(CXCL10) is implicated as a more potent predictive maker for
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virus-associated exacerbations, and it is known as IFN-λ-induced
protein 10.
TREATMENT OF STABLE AND EXACERBATION STATES
Inhaled bronchodilators, LAMA and LABA, are the main pharma-
cological therapies in stable COPD patients (Tashkin et al., 2008;
Wedzicha et al., 2008; Vestbo et al., 2013). Although Vogelmeier
et al. (2011) reported that the tiotropium (LAMA)-treated group
had a lower exacerbation rate than the salmeterol (LABA)-treated
group in their head-to-head study, both LAMA and LABA treat-
ments decreased exacerbation rates and improved lung function or
health-related quality of life. Tashkin et al. (2009) found that com-
bination LAMA/LABA therapy improved pulmonary function
(FEV1.0) and respiratory symptoms better than LAMA therapy
alone. ICS, the main treatment for asthma, is also prescribed
in COPD patients and may reduce airway inﬂammation and
decrease exacerbation rates only in moderate and severe COPD
patients (Calverley et al., 2007). Treatment with macrolide antibi-
otics has been reported to prevent COPD exacerbations and
improve patient quality of life and symptoms, especially in patients
who have frequent exacerbations (Albert et al., 2011; Yamaya et al.,
2012a), although this intervention could lead tounfavorable events
such as increasing the prevalence of macrolide-resistant pathogens
or cardiac toxicity.
It has been estimated that most exacerbations of COPD are
due to respiratory viral and/or bacterial infections. Thus, the
major pharmacological components of managing exacerbations
of COPD include SABAs, short-course systemic glucocorticoids,
and antibiotics (Vestbo et al., 2013). However, anti-viral therapies
are rarely prescribed, because speciﬁc anti-viral therapies do not
exist, except for inﬂuenza virus and RSV. Treatment for inﬂuenza
appears appropriate in patients with COPD (Harper et al., 2009),
while the utility of treatment for RSV has not been conﬁrmed in
adults. It is doubtful that systemic corticosteroid treatment affects
the clinical course of respiratory viral infections. Lee et al. (2011)
showed that short-course systemic steroid treatment did not affect
viral load or shedding, and humoral immunitymay be diminished
by steroid treatment.
Some research has shown that LAMA may affect viral infec-
tions. Tiotropium, one of the LAMAs, may inhibit HRV and
RSV infections by reducing the levels of intercellular adhesion
molecule-1, which is the binding site for most HRVs (Iesato et al.,
2008; Yamaya et al., 2012b).
SUMMARY AT A GLANCE
The associations between virus infections and asthma and/or
COPD were reviewed, and the signiﬁcance of viral infections, as
well as their effect on the clinical course, was discussed.
(1) HRV and RSV are major causes of exacerbations both in
asthma and COPD patients.
(2) The frequency of viral detection in both asthma and COPD
patients appears to be similar to that of healthy subjects, but
the effect on their clinical course is different; asthmaandCOPD
patients tend to have more severe or persistent respiratory
symptoms or decreases in pulmonary function, and mortality
may be increased.
(3) Since discrimination between asthma and COPD is difﬁcult,
especially during exacerbations,whenever clinicians encounter
patients in whom obstructive airway disease is suspected,
multidisciplinary assessment is required for diagnosis.
(4) The clinical ﬁndings of both asthma and COPD, so-called
“overlap syndrome,”are commonly recognized in general prac-
tice, and virus-associated exacerbations in this diseasemay lead
to a poor prognosis.
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